Ordinary and Extraordinary General Meeting of May 24, 2019 - Procedures for Obtaining Preparatory Documents for the General M...
May 06 2019 - 3:30AM
Montrouge,
France, May 3, 2019 |
Ordinary and Extraordinary General
Meeting of May 24, 2019
Procedures for Obtaining Preparatory
Documents for the General Meeting
DBV Technologies (Euronext: DBV – ISIN:
FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage
biopharmaceutical company, announced today that it will hold its
Ordinary and Extraordinary General Meeting on May 24, 2019 at 8:30
a.m. CEST at the Company’s headquarters located at 177-181 Avenue
Pierre Brossolette – 92120 Montrouge, France.
The preliminary notice (l'avis préalable)
containing the detailed agenda, draft resolutions as well as
instructions to participate and vote for this meeting was published
in the French “Bulletin des Annonces Légales Obligatoires (BALO)”
dated April 19, 2019. The notice of meeting (l'avis de convocation)
stating the time and place of the meeting will be published in the
BALO and in the Legal Gazette on May 6, 2019.
The preparatory documents for the General
Meeting listed in article R. 225-73-1 of the French Commercial Code
are posted on the Investors & Media section of the Company’s
website located at:
https://www.dbv-technologies.com/investor-relations/financial--information/annual-reports/
The documents for the General Meeting will also
be made available to shareholders as of the date of the issuance of
the convening notice. Thus, in accordance with applicable law and
regulations:
- Any shareholder holding registered shares may, until the fifth
day prior to the General Meeting, request that the Company send
them the documents required under articles L.225-115 and R.225-83
of the French Commercial Code, electronically at their express
request. For shareholders holding bearer shares, the exercise of
this right is subject to the submission of a certificate of
participation in the bearer share accounts held by the authorized
financial intermediary.
- Any shareholder may consult the documents and information
referred to in articles L.225-115 and R.225-83 of the French
Commercial Code, which are available at the Company’s
headquarters.
About DBV
Technologies
DBV Technologies is developing Viaskin®, a
proprietary technology platform with broad potential applications
in immunotherapy. Viaskin is based on epicutaneous immunotherapy,
or EPIT®, DBV’s method of delivering biologically active compounds
to the immune system through intact skin. With this new class of
self-administered and non-invasive product candidates, the Company
is dedicated to safely transforming the care of food allergic
patients, for whom there are no approved treatments. DBV’s food
allergies programs include ongoing clinical trials of Viaskin
Peanut and Viaskin Milk, and preclinical development of Viaskin
Egg. DBV is also pursuing a human proof-of-concept clinical study
of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and
exploring potential applications of its platform in vaccines and
other immune diseases. DBV Technologies has global headquarters in
Montrouge, France and New York, NY. The Company’s ordinary shares
are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code:
FR0010417345), part of the SBF120 index, and the Company’s ADSs
(each representing one-half of one ordinary share) are traded on
the Nasdaq Global Select Market (Ticker: DBVT).
DBV Investor Relations ContactSara
Blum ShermanSenior Director, Investor Relations & Strategy
+1 212-271-0740sara.sherman@dbv-technologies.com
DBV Media Contact Joe Becker VP,
Global Corporate Communications+1-646-650-3912
joseph.becker@dbv-technologies.com
DBV Technologies (NASDAQ:DBVT)
Historical Stock Chart
From Mar 2024 to Apr 2024
DBV Technologies (NASDAQ:DBVT)
Historical Stock Chart
From Apr 2023 to Apr 2024